With the rapid development of the biotherapeutic industry in Asia, the surge of companies developing biosimilars and the increase in companies outsourcing clinical trials to Asia, now is a critical time to understand, predict and minimize unwanted immunogenicity in biopharmaceutical and biosimilar development.
Immunogenicity poses a risk that should be assessed during drug development, as it possibly compromises drug safety and alters drug characteristics including pharmacokinetics and bioavailability. Immunogenicity assessment strategies combine pre-clinical predictive methods with clinical stage measurement of anti-drug antibodies.
Discover key updates in techniques applied by leading biopharm companies to ensure detection and prediction of immunogenicity throughout the drug development cycle at IBC’s inaugural Immunogenicity for Biopharmaceuticals & Biosimilars Asia.
Showcase your successes – share your latest research and findings in the immunogenicity field with a scientific poster.
To apply for a poster presentation:
- Register as a conference delegate
- Submit your abstract of 200 words or less, written in English, listing the principal author and all contact details to email@example.com by Monday 10 September 2012
- Posters submitted by academic and research institutions (non-commercial) will not be charged a fee
- Posters submitted by pharma/biopharm industry and service providers/vendors* (commercial) will be charged US $100 for the 2-day conference
*Approval is subject to evaluation by the scientific advisory board
Monday 10 September 2012
This event is designed to meet the needs of professionals working in the research, development and commercialization of biopharmaceuticals including:
Immunogenicity for Biopharmaceuticals & Biosimilars Asia is co-located with IBC’s 7th Annual Generics Asia Summit giving you access to 2 multidisciplinary audiences and shared networking space.
- Senior Scientists, Lab Head, Principal Scientists, Researchers, Biostatisticians, Directors at Asian biopharm, biosimilar and CROs
- Clinical Development Head, Clinical Research Head of international biopharm looking to outsource/offshore clinical trials to Asia
- CSOs, CEOs, Presidents of domestic biotherapy companies
- Professors, Research Associates, Scientists involved in immunology at domestic academic and research institutes